APDN · Applied Dna Sciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $1.30M | $2.41M | $7.83M | $4.54M | - | $720.9K |
| Gross Profit | $838.9K | $1.02M | $5.53M | $4.48M | - | - |
| R&D | $6.02M | $3.59M | $3.74M | $3.93M | $3.77M | $3.32M |
| SG&A | $10.87M | $11.45M | $12.75M | $15.10M | $12.61M | $10.14M |
| Total Operating Expenses | $16.89M | $15.04M | $16.49M | $19.02M | $18.04M | $13.75M |
| D&A | $384.2K | $696.4K | $1.36M | $1.29M | $844.4K | $285.7K |
| Operating Income | ($16.05M) | ($14.02M) | ($10.95M) | ($13.97M) | ($13.11M) | ($12.53M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($684.1K) | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($15.16M) | ($6.99M) | ($9.95M) | ($8.27M) | ($14.29M) | ($13.03M) |
| EPS - Basic | ($134.23) | ($1.82) | ($0.76) | ($0.93) | ($3.32) | - |
| EPS - Diluted | ($134.23) | ($1.82) | ($0.76) | ($0.93) | ($3.32) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.67M | $6.43M | $7.15M | $15.22M | $6.55M | $7.79M |
| Accounts Receivable | $237.4K | $362.0K | $255.5K | $3.07M | $2.80M | $194.3K |
| Inventory | $84.1K | $438.6K | $330.0K | $602.2K | $1.37M | $497.4K |
| Accounts Payable | $844.8K | $1.17M | $1.07M | $1.74M | $2.01M | $1.25M |
| Current Assets | $2.24M | $8.05M | $8.13M | $19.94M | $11.30M | $9.08M |
| Total Assets | $4.44M | $12.79M | $13.65M | $22.27M | $14.42M | $11.34M |
| Current Liabilities | $2.46M | $2.40M | $2.85M | $4.19M | $3.27M | $4.27M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $2.50M | $3.82M | $8.78M | $9.36M | $3.30M | $5.63M |
| Stockholders' Equity | $2.30M | $9.14M | $4.95M | $12.91M | $11.11M | $5.72M |
| Retained Earnings | ($379.16M) | ($309.67M) | ($302.45M) | ($292.50M) | ($284.12M) | ($269.84M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.59M) | ($13.71M) | ($6.22M) | ($8.98M) | ($13.39M) | ($11.14M) |
| Investing Cash Flow | ($407.9K) | ($407.9K) | ($1.10M) | ($489.6K) | ($2.55M) | ($1.06M) |
| Financing Cash Flow | $8.05M | $13.40M | - | $18.13M | $14.70M | $19.43M |
| CapEx | $313.1K | $407.9K | $78.4K | $489.6K | $2.55M | $1.06M |
| Free Cash Flow | ($13.90M) | ($14.12M) | ($6.30M) | ($9.47M) | ($15.94M) | ($12.21M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.92 | 2.02 | 0.63 | 1.14 | 1.12 | 0.94 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -341.7% | -54.7% | -72.9% | -37.1% | -99.1% | -114.9% |
| Return on equity | -657.8% | -76.5% | -200.9% | -64.0% | -128.5% | -227.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.91 | 3.36 | 2.86 | 4.77 | 3.45 | 2.13 |
| Quick ratio | 0.87 | 3.17 | 2.74 | 4.62 | 3.03 | 2.01 |
| Cash ratio | 0.68 | 2.68 | 2.51 | 3.64 | 2.00 | 1.83 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.93 | 1.40 | 2.76 | 1.72 | 1.30 | 1.98 |
| Liabilities / Assets | 0.56 | 0.30 | 0.64 | 0.42 | 0.23 | 0.50 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 15.43 | 5.51 | 23.74 | 7.55 | - | 1.45 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 24d | 66d | 15d | 48d | - | 252d |
| Days payable outstanding | 238d | 176d | 50d | 140d | - | 633d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | -17.5% | -81.6% | 23.4% | - | - | - |
| Operating income growth (YoY) | -14.4% | -28.0% | 21.6% | -6.5% | -4.6% | -37.4% |
| Net income growth (YoY) | -116.8% | 29.7% | -20.3% | 42.1% | -9.7% | -51.1% |
| EPS growth (YoY) | -7275.3% | -139.5% | 18.3% | 72.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 1.5% | -124.3% | 33.5% | 40.6% | -30.6% | -76.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -74.8% | 84.7% | -61.7% | 16.2% | 94.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-Testing Laboratories
Comparing APPLIED DNA SCIENCES INC against the 4 most active filers in the same SIC group.